Miranda Schmalfuhs
Miranda Schmalfuhs is the associate group social media editor of Pharmaceutical Executive, Pharmaceutical Commerce, and Applied Clinical Trials and can be reached at mschmalfuhs@mjhlifesciences.com.
Articles
Pharmacy Closure Contributors & Long-Term Consequences
June 27th 2024In this part of his Pharmaceutical Executive video interview, Michael Abrams, Managing Partner, Numerof & Associates, identifies the main factors contributing to closures of pharmacies big and small and some potential long-term consequences for public health if they continue.
Pharmacy Deserts & Underserved/Rural Communities
June 26th 2024In this part of his Pharmaceutical Executive video interview, Michael Abrams, Managing Partner, Numerof & Associates, speaks about the specific challenges that pharmacy deserts becoming a national issue presents for rural and underserved areas. Plus a discussion of which alternative solutions can help ensure continued access to medications for all.
Advice for Investors Entering Weight-Loss Market
June 18th 2024In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, shares advice for investors and financiers who are considering entering the weight-loss medication market.
Ensuring Ethical Practices in Light of Potential Misuse
June 17th 2024In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, talks about what steps companies developing weight-loss medications should take to ensure responsible and ethical practices.
What Needs to be Done to Cover GLP-1?
June 14th 2024In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, and what needs to be done for GLP-1s to be covered.
Top GLP-1 Legal & Regulatory Concerns for Investors
June 13th 2024In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses the top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs.
Using OpenAI to Accelerate the Development and Launch of Upcoming mRNA Medicines
June 12th 2024In this part of his Pharmaceutical Executive video interview, Brice Challamel, Vice President, AI Products & Platforms, Moderna, talks about how Moderna will leverage its collaboration with OpenAI to accelerate the development and launch of its upcoming mRNA medicines
Challenges Integrating GenAI into Various Departments
June 10th 2024In this part of his Pharmaceutical Executive video interview, Brice Challamel, Vice President, AI Products & Platforms, Moderna, speaks about challenges Moderna faced integrating generative AI,like mChat and GPTs, into its various departments and how they overcame them.
Pharm Exec Exclusive: Mark Cuban Talks Drug Pricing
June 7th 2024Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.
